Reverse Transcriptase News and Research

RSS
Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride

Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride

FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA

FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA

FDA approves 200 mg formulation of INTELENCE for HIV-1

FDA approves 200 mg formulation of INTELENCE for HIV-1

Bristol-Myers Squibb, Oncolys complete license agreement for festinavir

Bristol-Myers Squibb, Oncolys complete license agreement for festinavir

Matrix's NDA for Abacavir Sulfate receives tentative FDA approval under PEPFAR

Matrix's NDA for Abacavir Sulfate receives tentative FDA approval under PEPFAR

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

ViiV Healthcare awards $20 million to Idenix for GSK2248761 clinical milestone

ViiV Healthcare awards $20 million to Idenix for GSK2248761 clinical milestone

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

Phase III study influences WHO to change guidelines for HIV-infected women receiving nevirapine

Phase III study influences WHO to change guidelines for HIV-infected women receiving nevirapine

MTN-007 phase trial evaluates vaginal microbicide to prevent rectal transmission of HIV

MTN-007 phase trial evaluates vaginal microbicide to prevent rectal transmission of HIV

Researchers discover HIV-1 resists AZT drug

Researchers discover HIV-1 resists AZT drug

Tibotec submits MAA for investigational HIV drug TMC278 to European Medicines Agency

Tibotec submits MAA for investigational HIV drug TMC278 to European Medicines Agency

Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection

Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection

GoTaq 2-Step RT-qPCR System allows researchers to detect target genes

GoTaq 2-Step RT-qPCR System allows researchers to detect target genes

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Tibotec submits NDA for TMC278 anti-HIV compound to FDA

Tibotec submits NDA for TMC278 anti-HIV compound to FDA

New HIV drug on the block

New HIV drug on the block